Anaveon CEO Andreas Katopodis and Syncona CEO Martin Murphy discuss the encouraging news that Anaveon has dosed its first patient in a Phase I/II study of ANV419.
- About
- Our people
- Portfolio
- Sustainability
- The Foundation
- News & insights
- Investors
- Contact
